Please assess the completion status of the following clinical trial:

Trial Title: Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Duration of SCI ≥1 year;~* Level of SCI C3-T1, AIS A \& B;~* Age between 18 and 65 years.~Exclusion Criteria:~* Evidence of sympathetic integrity below the lesion level by the skin axon-reflex vasodilatation (SkARV) test;~* Known allergies to midodrine hydrochloride;~* PMH of diagnosed heart, kidney, peripheral vascular, or cerebral vascular disease, or diabetes mellitus;~* Hypertension (BP\>140/90 mmHg);~* Untreated thyroid disease;~* Acute illness or infection;~* Current smoker;~* Pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Cool Temperature Exposure / No Drug (Type: EXPERIMENTAL): Subjects are persons with tetraplegia: spinal cord lesion level C3 to T1, AIS levels A and B, ages 18-65 years or subjects are able-bodied controls matched for age and gender. Procedure is exposure to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 1).
- Cool Temperature Exposure with Drug (Type: EXPERIMENTAL): Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).

Based on this trial design, predict the completion outcome and termination type (if applicable).